menu
    • menu

    Company profile for Noxopharm

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Noxopharm is an Australian publicly-listed (ASX: NOX) clinical stage drug development company. The clinical stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug candidate designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy. At one level, Veyonda® enhances the cancer-killing effect of standard chemotherap...
    Noxopharm is an Australian publicly-listed (ASX: NOX) clinical stage drug development company. The clinical stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug candidate designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy. At one level, Veyonda® enhances the cancer-killing effect of standard chemotherapy and radiotherapy, thereby enabling lower doses of these toxic therapies to be used.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NoxopharmAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    Level 4, 828 Pacific Highway Gordon.
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.noxopharm.com/site/content/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/noxopharm-limited/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/noxopharm

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Australia's Noxopharm scales up production of lupus medication
    Australia's Noxopharm scales up production of lupus medication

    18 May 2024

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/25/24259/australias-noxopharm-scales-up-production-of-lupus-medication.html

    BIOSPECTRUM ASIA
    18 May 2024
    Share Share
    Australia's Noxopharm receives A$1.45M grant for inflammation-based research
    Australia's Noxopharm receives A$1.45M grant for inflammation-based research

    27 Jun 2022

    // BIOSPECTRUMASIA

    https://www.biospectrumasia.com/news/25/20571/australias-noxopharm-receives-a1-45m-grant-for-inflammation-based-research.html

    BIOSPECTRUMASIA
    27 Jun 2022
    Share Share
    FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
    FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

    29 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220329005209/en

    BUSINESSWIRE
    29 Mar 2022
    Share Share
    Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles
    Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles

    08 Mar 2022

    // PRESS RELEASE

    https://www.scorrmarketing.com/about-us/news/sarcoma-trial-for-new-cancer-treatment-begins-at-city-of-hope-in-los-angeles/

    PRESS RELEASE
    08 Mar 2022
    Share Share
    Here’s why the Noxopharm (ASX: NOX) share price leapt 7% today
    Here’s why the Noxopharm (ASX: NOX) share price leapt 7% today

    13 Dec 2021

    // FOOL

    https://www.fool.com.au/2021/12/14/heres-why-the-noxopharm-asx-nox-share-price-leapt-7-today/

    FOOL
    13 Dec 2021
    Share Share
    Noxopharm In-Licenses Novel RNA Technology From HIMR
    Noxopharm In-Licenses Novel RNA Technology From HIMR

    01 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211201005240/en

    BUSINESSWIRE
    01 Dec 2021
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search